Falsely Low Fibrinogen Levels in COVID-19 Patients on Direct Thrombin Inhibitors.
作者信息
Maier Cheryl L, Barker Nicholas A, Sniecinski Roman M
机构信息
Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia.
Department of Pharmacy, Emory St Joseph's Hospital, Atlanta, Georgia.
出版信息
Anesth Analg. 2020 Aug;131(2):e117-e119. doi: 10.1213/ANE.0000000000004949.
Abstract
摘要
相似文献
1
Falsely Low Fibrinogen Levels in COVID-19 Patients on Direct Thrombin Inhibitors.接受直接凝血酶抑制剂治疗的COVID-19患者纤维蛋白原水平假性降低
Anesth Analg. 2020 Aug;131(2):e117-e119. doi: 10.1213/ANE.0000000000004949.
2
All those D-dimers in COVID-19.新冠病毒感染病例中的所有这些D-二聚体。
J Thromb Haemost. 2020 Aug;18(8):2075-2076. doi: 10.1111/jth.14939. Epub 2020 Jun 25.
3
Coronavirus blood-clot mystery intensifies.新冠病毒引发的血液凝块之谜愈发难解。
Nature. 2020 May;581(7808):250. doi: 10.1038/d41586-020-01403-8.
4
Hypoalbuminemia and elevated D-dimer in COVID-19 patients: a call for result harmonization.新型冠状病毒肺炎患者的低白蛋白血症和D-二聚体升高：呼吁结果统一
Clin Chem Lab Med. 2020 Oct 25;58(11):e255-e256. doi: 10.1515/cclm-2020-1038.
5
D-dimer Triage for COVID-19.新冠病毒病的D-二聚体分诊
Acad Emerg Med. 2020 Jul;27(7):612-613. doi: 10.1111/acem.14037. Epub 2020 Jun 24.
6
Megakaryocytes: Masters of Innate Immunity?巨核细胞：先天免疫的掌控者？
Arterioscler Thromb Vasc Biol. 2020 Dec;40(12):2812-2814. doi: 10.1161/ATVBAHA.120.315471. Epub 2020 Nov 24.
7
Re The source of elevated plasma D-dimer levels in COVID-19 infection.关于新冠病毒感染中血浆D-二聚体水平升高的来源。
Br J Haematol. 2020 Aug;190(3):e133-e134. doi: 10.1111/bjh.16907. Epub 2020 Jun 18.
8
COVID-19 and thrombotic complications: Pulmonary thrombosis rather than embolism?新型冠状病毒肺炎与血栓形成并发症：是肺血栓形成而非肺栓塞？
Thromb Res. 2020 Sep;193:98. doi: 10.1016/j.thromres.2020.06.014. Epub 2020 Jun 8.
9
D-dimer is associated with the risk of mortality in Coronavirus Disease 2019 patients.D-二聚体与2019冠状病毒病患者的死亡风险相关。
Eur Rev Med Pharmacol Sci. 2020 Aug;24(16):8576-8579. doi: 10.26355/eurrev_202008_22655.
10
d-Dimer and COVID-19.D-二聚体与新型冠状病毒肺炎
Radiology. 2020 Dec;297(3):E343-E344. doi: 10.1148/radiol.2020203481. Epub 2020 Oct 13.
引用本文的文献
1
A Novel Fibrinogen Assay Using Recombinant Batroxobin and Carboxymethyl Chitosan: Carboxymethyl Chitosan Stimulates the Enzymatic Activity of Recombinant Batroxobin.一种使用重组巴曲酶和羧甲基壳聚糖的新型纤维蛋白原测定法：羧甲基壳聚糖刺激重组巴曲酶的酶活性。
Ann Lab Med. 2025 Sep 1;45(5):484-492. doi: 10.3343/alm.2024.0688. Epub 2025 Jun 12.
2
Emerging patterns of hypercoagulability associated with critical COVID-19: A review.与重症新型冠状病毒肺炎相关的高凝状态新趋势：综述
Trends Anaesth Crit Care. 2020 Oct;34:4-13. doi: 10.1016/j.tacc.2020.07.004. Epub 2020 Jul 9.
3
Viscoelastometric Testing to Assess Hemostasis of COVID-19: A Systematic Review.用于评估新型冠状病毒肺炎止血功能的粘弹性测试：一项系统评价
J Clin Med. 2021 Apr 16;10(8):1740. doi: 10.3390/jcm10081740.
4
The role of rotational thromboelastometry during the COVID-19 pandemic: a narrative review.在 COVID-19 大流行期间旋转血栓弹性测定仪的作用：叙述性综述。
Korean J Anesthesiol. 2021 Apr;74(2):91-102. doi: 10.4097/kja.21006. Epub 2021 Jan 13.
5
Therapeutic plasma exchange for COVID-19-associated hyperviscosity.COVID-19 相关高黏滞血症的治疗性血浆置换。
Transfusion. 2021 Apr;61(4):1029-1034. doi: 10.1111/trf.16218. Epub 2020 Dec 9.
6
COVID-19-Associated Coagulopathy and Inflammatory Response: What Do We Know Already and What Are the Knowledge Gaps?COVID-19 相关凝血功能障碍与炎症反应：我们已经了解了什么，还有哪些知识空白？
Anesth Analg. 2020 Nov;131(5):1324-1333. doi: 10.1213/ANE.0000000000005147.
7
In Response.作为回应。
Anesth Analg. 2020 Aug;131(2):e119-e120. doi: 10.1213/ANE.0000000000004950.
8
Management of the thrombotic risk associated with COVID-19: guidance for the hemostasis laboratory.新型冠状病毒肺炎相关血栓形成风险的管理：止血实验室指南
Thromb J. 2020 Sep 7;18:17. doi: 10.1186/s12959-020-00230-1. eCollection 2020.
本文引用的文献
1
ISTH interim guidance on recognition and management of coagulopathy in COVID-19.国际血栓与止血学会（ISTH）关于新冠病毒病（COVID-19）凝血病识别与管理的临时指南。
J Thromb Haemost. 2020 May;18(5):1023-1026. doi: 10.1111/jth.14810. Epub 2020 Apr 27.
2
Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia.异常的凝血参数与新型冠状病毒肺炎患者的预后不良有关。
J Thromb Haemost. 2020 Apr;18(4):844-847. doi: 10.1111/jth.14768. Epub 2020 Mar 13.
3
Trials and Tribulations of Viscoelastic-Based Determination of Fibrinogen Concentration.基于黏弹性的纤维蛋白原浓度测定的试验与磨难。
Anesth Analg. 2020 Mar;130(3):644-653. doi: 10.1213/ANE.0000000000004522.
4
Monitoring of argatroban and lepirudin anticoagulation in critically ill patients by conventional laboratory parameters and rotational thromboelastometry - a prospectively controlled randomized double-blind clinical trial.通过传统实验室参数和旋转血栓弹力图监测危重症患者的阿加曲班和比伐芦定抗凝治疗——一项前瞻性对照随机双盲临床试验
BMC Anesthesiol. 2018 Feb 9;18(1):18. doi: 10.1186/s12871-018-0475-y.
5
Influences of argatroban on five fibrinogen assays.阿加曲班对五种纤维蛋白原检测方法的影响。
Int J Lab Hematol. 2017 Dec;39(6):641-644. doi: 10.1111/ijlh.12719. Epub 2017 Aug 2.
6
Low plasma fibrinogen levels with the Clauss method during anticoagulation with bivalirudin.
Anesthesiology. 2008 Jul;109(1):160-1. doi: 10.1097/ALN.0b013e31817885b7.
Zotero 插件